Answers are grounded in this paper and cite their sources.
Background: Cardiac stereotactic body radiation therapy (SBRT) and dapagliflozin (DAPA) act on overlapping electrophysiological pathways, but whether cardiac irradiation alters DAPA disposition is unknown. Methods: Male Sprague-Dawley rats received sham irradiation, 2-Gy whole-heart irradiation, or 12-Gy irradiation of a central 1.0 × 1.0 cm cardiac field, followed by oral DAPA (3 mg/kg) 2 h (2 h post-RT) or 24 h (24 h post-RT) later. Plasma DAPA was measured by HPLC-UV over 240 min for non-compartmental analysis (n = 6/group); heart, liver, and kidney concentrations were measured once, 4 h after dosing (n = 5/group). Groups were compared by Welch ANOVA with Games–Howell tests (Kruskal–Wallis for Tmax). Results: AUC0–240 did not differ significantly among groups (247–305 min·µg/mL; p = 0.66), although confidence intervals were wide. Tmax was numerically longer in the 2-Gy 2 h post-RT group (190 ± 24 vs. 100 ± 31 min), but the Kruskal–Wallis test was not significant (p = 0.090). Terminal-phase parameters (t1/2, MRT, CL/F, Vss/F) were treated as exploratory because 40–63% of AUC0–∞ was extrapolated; none differed significantly. At 4 h, renal DAPA was lower in the 12-Gy 24 h post-RT group (23.52 ± 2.40 vs. 56.09 ± 2.45 µg/g; p < 0.001), and hepatic DAPA was higher in the 2-Gy 24 h post-RT group (17.32 ± 3.17 vs. 6.67 ± 1.58 µg/g; p = 0.003); cardiac concentrations did not differ significantly from control. Conclusions: In this exploratory study, cardiac irradiation did not produce a detectable change in early systemic DAPA exposure. The single-time-point organ differences are hypothesis-generating and do not establish altered tissue exposure; whether DAPA timing relative to cardiac SBRT matters clinically requires dedicated study.
No takes yet. Share an insight, caveat, or question.
Hsieh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: